| Released | Contributor | Author | Title | Pages | Price |
| 29-Nov-2009 | PriceTarget Research, Inc. |
N/A
| BCRX has a current Overall Rating of C (Neutral). | 7 |
$25 |
| 28-Nov-2009 | Standard & Poor's Quantitative Report |
N/A
| BioCryst Pharm'l | 6 |
$25 |
| 27-Nov-2009 | Pechala's Reports | Lubomir Pechala | BIOCRYST PHARMACEUTICALS INC (BCRX=US) 2-weeks forecast | 1 |
$10 |
| 27-Nov-2009 | Pechala's Reports | Frantisek Pechala | BIOCRYST PHARMACEUTICALS INC (BCRX=US) 12-months forecast | 1 |
$15 |
| 26-Nov-2009 | ValuEngine, Inc. |
N/A
| ValuEngine Industry Report for BIOTECHNOLOGY | 18 |
$49 |
| 26-Nov-2009 | Ford Investor Services, Inc. |
N/A
| Industry Value Graph: ARRY , BCRX , DNDN , GERN , XOMA -- DRUGS | 3 |
$4 |
| 26-Nov-2009 | Ford Investor Services, Inc. |
N/A
| Value Graph: BIOCRYST PHARM -- BCRX | 1 |
$4 |
| 26-Nov-2009 | New Constructs, LLC |
N/A
| BCRX: Risk/Reward Rating: Full Report: Cash Truth Behind the Reported Earnings | 19 |
$10 |
| 24-Nov-2009 | Directors Deals Ltd. | Company Snapshot | Company Snapshot - Biocryst Pharmaceuticals Inc | 1 |
$10 |
| 23-Nov-2009 | PriceTarget Research, Inc. |
N/A
| Biotechnology Intelligence Monitor: overall outlook STRONG - 25 new Leaders; 18 new Laggards. | 58 |
$20 |
1.48% Nasdaq 
Research Reports
